ArticleEuropean journal of medicinal chemistry2015
Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.
Article in European journal of medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Medicinal Plants in the Treatment of Tuberculosis: A Systematic Review.Central nervous system agents in medicinal chemistry · 2025Pooled it
- Traditional Medicinal Plants as a Source of Antituberculosis Drugs: A System Review.BioMed research international · 2021Pooled it
- Development and application of a curcumin-cinnamon essential oil nanoemulsion agent against mycobacteria.Frontiers in cellular and infection microbiology · 2025Article
- Repurposed Drugs and Plant-Derived Natural Products as Potential Host-Directed Therapeutic Candidates for Tuberculosis.Biomolecules · 2024Review
- Preliminary insight on diarylpentanoids as potential antimalarials: In silico, in vitroHeliyon · 2024Article
- Michael acceptor molecules in natural products and their mechanism of action.Frontiers in pharmacology · 2022Review
- Antibiofilm Activity ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals.MedComm · 2021Review
- Therapeutic Potential of Curcumin as an Antimycobacterial Agent.Biomolecules · 2021Review
- Curcumin Nanoformulations with Metal Oxide Nanomaterials for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Effects of Curcumin and Its Analogues on Infectious Diseases.Advances in experimental medicine and biology · 2021Review
- Synthesis and bioactivity evaluation of penta-1,4-diene-3-one oxime ether derivatives.Journal of pesticide science · 2019Article
- Article
- Phytochemical Evaluation, Embryotoxicity, and Teratogenic Effects ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.Molecular medicine reports · 2018Article
- Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.Journal of medicinal chemistry · 2017Article
- Anti-mycobacterium tuberculosis activity of polyherbal medicines used for the treatment of tuberculosis in Eastern Cape, South Africa.African health sciences · 2017Article
- Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review.Journal of traditional and complementary medicine · 2017Review
- Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection withFrontiers in immunology · 2017Article
- Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.Pharmaceuticals (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Tuberculosis (TB) is a major public health concern worldwide with over 2 billion people currently infected. The rise of strains of Mycobacterium tuberculosis (Mtb) that are resistant to some or all first and second line antibiotics, including multidrug-resistant (MDR), extensively drug resistant (XDR) and totally drug resistant (TDR) strains, is of particular concern and new anti-TB drugs are urgently needed. Curcumin, a natural product used in traditional medicine in India, exhibits anti-microbial activity that includes Mtb, however it is relatively unstable and suffers from poor bioavailability. To improve activity and bioavailability, mono-carbonyl analogs of curcumin were synthesized and screened for their capacity to inhibit the growth of Mtb and the related Mycobacterium marinum (Mm). Using disk diffusion and liquid culture assays, we found several analogs that inhibit in vitro growth of Mm and Mtb, including rifampicin-resistant strains. Structure activity analysis of the analogs indicated that Michael acceptor properties are critical for inhibitory activity. However, no synergistic effects were evident between the monocarbonyl analogs and rifampicin on inhibiting growth. Together, these data provide a structural basis for the development of analogs of curcumin with pronounced anti-mycobacterial activity and provide a roadmap to develop additional structural analogs that exhibit more favorable interactions with other anti-TB drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.